We are thrilled to share an exclusive presentation by Professor Jianxiang Wang from the Institute of Hematology, Chinese Academy of Medical Sciences. In this engaging session, Professor Wang delves into the groundbreaking findings of the Phase 3 Commodore study, recently published in Leukemia. This study provides critical new evidence on the efficacy of gilteritinib, a FLT3-inhibiting TKI, in treating relapsed or refractory FLT3-mutated acute myeloid leukemia (AML) among predominantly Asian patients.
Key highlights from the study include:
Improved overall survival compared to salvage chemotherapy
Promising results across multiple subgroups
A favorable safety profile tailored to the needs of Asian patients
Join us in exploring this milestone in hematology research that paves the way for improved therapeutic strategies in AML management. Watch now to learn more!
